Abstract:Abstract Background Breast cancer is one of the most important causes of mortality in the world, and Tamoxifen therapy is known as a medication strategy for estrogen receptor-positive breast cancer. In current study, two hypotheses of Tamoxifen consumption in breast cancer cell line ( MCF7 ) were investigated. First, the effect of Tamoxifen on genes expression profile at transcriptome level was evaluated between the control and treated samples. Second, due to the fact that Tamoxifen is known as a mutagenic factor, there may be an association between the alterations of genetic variants and Tamoxifen treatment, which can impact on the drug response. Methods In current study, the whole-transcriptome (RNA-seq) dataset of four investigations (19 samples) were derived from European Bioinformatics Institute (EBI). At transcriptome level, the effect of Tamoxifen was investigated on gene expression profile between control and treatment samples. Moreover, Tamoxifen is known as a mutagenic factor, therefore, its contribution to alterations of genetic variants and drug response were examined. Results Results achieved from RNA-seq analysis indicated the contribution of several candidate genes to tumor suppression process and consequently, the achievement of an effective treatment. For instance, XIAP -associated factor 1 ( XAF1 ) was reported as an up-regulated gene under Tamoxifen therapy. XAF1 is a tumor suppressor that contributes to the apoptosis induction and tumor growth inhibition along with TP53 . Results of gene ontology enrichment analysis of differential gene expressions indicated that most of them could considerably lead to the cell death, apoptosis, and negative regulation of proteolysis process. Findings achieved from evaluating Tamoxifen mutagenicity effect on drug response was not confirmed perfectly. The most reported candidate genes, which were related to differential genetic variants between control and treated samples, played the oncogene and tumor suppressor dual roles and also their exact roles in breast cancer were not investigated precisely. Conclusion At transcriptome level, Tamoxifen consumption in MCF7 cell line could be associated with candidate genes and biological pathways that contribute to the apoptosis, proteolysis, and tumor suppression. The mutagenicity effect of Tamoxifen and its contribution to drug response was not confirmed perfectly.

Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice

Tamoxifen Induces Fatty Liver Disease in Breast Cancer Through the MAPK8/FoxO Pathway

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice

Tamoxifen Protects Against Acute Tumor Necrosis Factor Α-Induced Cardiac Injury Via Improving Mitochondrial Functions

Short-term Tamoxifen Treatment Has Long-Term Effects on Metabolism in High-Fat Diet-Fed Mice with Involvement of Nmnat2 in POMC Neurons

Tamoxifen affects chronic pancreatitis‐related fibrogenesis in an experimental mouse model: an effect beyond Cre recombination

Tamoxifen induced cardiac damage via the IL-6/p-STAT3/PGC-1α pathway

Oxidative Stress in the Testis Induced by Tamoxifen and Its Effects on Early Embryo Development in Isogenic Mice

Persistent Metabolic Effects of Tamoxifen: Considerations for an Experimental Tool and Clinical Breast Cancer Treatment

Effects of tamoxifen and ethynylestradiol cotreatment on uterine gene expression in immature, ovariectomized mice

Potential risk of tamoxifen: gut microbiota and inflammation in mice with breast cancer

Vitamin D inhibits tamoxifen-induced non-alcoholic fatty liver disease through a nonclassical estrogen receptor/liver X receptor pathway

Human breast cancer in the athymic nude mouse: Cystostatic effects of long-term antiestrogen therapy

Tamoxifen administration induces histopathologic changes within the lungs of Cre-recombinase-negative mice: A case report

Alterations of Genetic Variants and Transcriptomic Features of Response to Tamoxifen in the Breast Cancer Cell Line

Tamoxifen Attenuates Lipopolysaccharide/Galactosamine-induced Acute Liver Failure by Antagonizing Hepatic Inflammation and Apoptosis

Confounding influence of tamoxifen in mouse models of Cre recombinase-induced gene activity or modulation

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways.